Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 13/20 | 0.70 |
| ▸ | GRM5 | P41594 | 4/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.48 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13089829 | 0.91 | MET (0.68) | METGRM5CNR2 | |
| SCHEMBL13089711 | 0.91 | MET (0.69) | METGRM5CNR2 | |
| SCHEMBL3063149 | 0.83 | MET (0.80) | MET | |
| SCHEMBL14290572 | 0.83 | MET (0.71) | MET | |
| SCHEMBL14960677 | 0.83 | MET (0.71) | MET | |
| SCHEMBL3053823 | 0.82 | MET (0.79) | MET | |
| SCHEMBL3047119 | 0.82 | MET (1.00) | MET | |
| SCHEMBL3063229 | 0.80 | MET (0.75) | MET | |
| SCHEMBL1301968 | 0.79 | MET (0.73) | MET | |
| SCHEMBL3057673 | 0.79 | MET (0.67) | MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9221806-B2 | 2-(heterocyclylbenzyl)pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2015-12-29 | — | — | US | disclosed |
| US-20130131037-A1 | 2-(HETEROCYCLYLBENZYL)PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2013-05-23 | — | — | US | disclosed |
| US-8435981-B2 | 2-(heterocyclylbenzyl)pyridazinone derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131037-A1 | 2-(HETEROCYCLYLBENZYL)PYRIDAZINONE DERIVATIVES | RET, MET, ERBB2 | MET 2/4885GRM5 1209/4885CNR2 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.